Key facts, as of
As of November 6, 2026, Quest Diagnostics (DGX) trades at $255.63, up 44.8% over the past year. Its 52-week range runs from $171.18 to $259.00; the price is 1.3% below that high. It is 1.3% below its all-time high of $259.00, reached in November 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +276.4%, against +316.3% for the S&P 500 (SPY). It sits 19.6% above its 200-day average of $213.79, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 21.3% annualized, which we rate medium risk. It has a trailing P/E of 25.5 and a dividend yield of 1.35%.
Cite: Portfolio Terminal, "Quest Diagnostics (DGX) stock analysis", 2026-11-06. https://portfolio-terminal.com/analyse/dgx
Where it trades today
trading 96% of the way up its 52-week range
How the price has moved
How far it is from its record
Quest Diagnostics (DGX) is 1.3% below its all-time high of $259.00, reached in November 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +276.4%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- DGX closes above its 50-day average ($239.37), and the 50-day sits above the 200-day ($213.79): on both averages the chart reads as an uptrend.
- At $255.63, DGX is 1.3% below its 1-year high of $259.00, set on November 5, 2026, and 49.3% above its 1-year low of $171.18 (January 5, 2026).
- Over the past month DGX rose 10.8%, from $230.81 to $255.63.
- DGX trades at 25.5x its last twelve months of earnings and 21.3x the next twelve months' estimate, so analysts expect earnings 19.3% higher.
- Its P/E is 30.5% below the 36.6x median of the 3 other diagnostics & research companies we track (TMO, DHR, A).
- DGX's 30-day volatility, 21.3% a year, works out to a typical daily move of about 1.3%.
- Yahoo Finance puts its beta at 0.55: over five years of monthly returns, DGX moved about 0.55% for each 1% move of the S&P 500.
What would change the read
- A close under the 50-day average, $239.37 (−6.4% from the last close), would turn the read to a pullback; under the 200-day, $213.79 (−16.4%), the longer rise is in question.
- A close above $259.00 (+1.3%) would be a new 1-year high; below $171.18 (−33.0%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for DGX, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under diagnostics & research among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for DGX by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for DGX. Last refresh: Nov 8, 2026, 10:53 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Diagnostics & Research.
What Quest Diagnostics does
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service…
Employees
60,000
Industry
Diagnostics & Research
Headquarters
Secaucus, United States
What analysts expect
DGX carries a buy consensus from 15 analysts, with an average price target of $257.27 versus $255.63 today (+0.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DGX generated $11.84B in trailing revenue (10.0% year over year), with a 9.5% net margin, and $872.50M of free cash flow, against $5.60B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $11.04B | $3.67B | $1.56B | $992.00M | $8.87 | $1.36B |
| 2024 | $9.87B | $3.24B | $1.35B | $871.00M | $7.78 | $909.00M |
| 2023 | $9.25B | $3.05B | $1.26B | $854.00M | $7.59 | $864.00M |
| 2022 | $9.88B | $3.43B | $1.43B | $946.00M | $8.10 | $1.31B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
DGX is in 17 of the 54 ETFs we track. It weighs most in XLV: 0.40% of the fund, holding #44 of 62.
How its figures compare with those peers
Companies in the same industry
DGX beside the other companies Yahoo Finance files under diagnostics & research among the assets we track (TMO, DHR, A, largest first).
DGXyou are here$255.63$28.21B
TMOThermo Fisher Scientific$694.76$257.42BDHDHRDanaher Corporation$230.25$161.99B
AAgilent Technologies$174.76$49.28BWhat the chart is saying
In an uptrend, 1.3% under its 1-year high with no resistance above.
uptrend- Price is 6.8% above its 50-day average and 19.6% above its 200-day.
- RSI at 67 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $248.01 (-3.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is DGX valued right now?
Quest Diagnostics trades at 25.5 times its last twelve months of earnings and 21.3 times the next twelve months' estimate (Yahoo Finance, November 6, 2026). On the chart: in an uptrend, 1.3% under its 1-year high with no resistance above. Price is 6.8% above its 50-day average and 19.6% above its 200-day.
What is the risk level of DGX?
Based on 30-day volatility of 21.3%, DGX has MEDIUM risk. Its beta of 0.55 means it has swung less than the S&P 500 over the last five years.
Does DGX pay dividends?
Yes, Quest Diagnostics has a dividend yield of 1.35%.
How far is DGX from its all-time high?
Quest Diagnostics is 1.3% below its all-time high of $259.00, reached in November 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +276.4%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold DGX?
17 of the 54 popular ETFs we track hold Quest Diagnostics. The largest weights: XLV (0.40%), VO (0.25%), RSP (0.20%), VIG (0.11%) and VYM (0.11%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is DGX?
0.04%, as of September 30, 2026: DGX is holding #331 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.39 in Quest Diagnostics.
What is the analyst price target for DGX?
The average analyst price target for Quest Diagnostics (DGX) is $257.27 based on 15 analyst estimates, about 0.6% above the current price of $255.63. The published range runs from $235.00 to $279.00.
How much revenue does DGX generate?
Quest Diagnostics reported $11.84B in trailing twelve-month revenue. Revenue growth is running at 10.0% year over year. Net margin sits at 9.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare DGX with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.